Protagonist Therapeutics (PTGX) Announces FDA Granted Orphan Drug Designation for PTG-300 for Treatment of Beta-Thalassemia

March 6, 2018 4:35 PM

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found